Is DexCom, Inc. (DXCM) a Buy, Sell, or Hold?
DexCom, Inc.
NASDAQ:DXCM
$72.73 USD
-$1.39 (-1.88%)
- Volume
- 4.08M
- Average Volume
- 5.74M
- Market Capitalization
- $28.06B
- P/E Ratio
- 30.30
- Dividend Yield
- 0.00%
- Price Target
- $85.50
- Year High
- $89.98
- Year Low
- $54.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.95
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jacob Steven Leach |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | DXCM |
| CUSIP | 252131107 |
| CIK | 0001093557 |
| Web | https://www.dexcom.com |
| Phone | 858 200 0200 |
| Currency | USD |
| Employees | 11100 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.47 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.95 |
| Quick Ratio | 1.64 |
| Cash Ratio | 0.50 |
Sales & Book Value
| Annual Sales | $4.66B |
| Price / Sales | 5.83 |
| Cash Flow | 3.71 |
| Price / Cash Flow | 19.63 |
| Price / Book | 9.47 |
Price Target and Rating
| Average Stock Price Forecast | $85.50 |
| High Stock Price Forecast | $95.00 |
| Low Stock Price Forecast | $64.00 |
| Forecast Upside/Downside | -14.94% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 52 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.09 |
| Trailing P/E Ratio | 30.30 |
| PEG Ratio | 0.40 |
| P/E Growth | 0.40 |
| Net Income | $836.3M |
| Net Margin | 19.31% |
| Pretax Margin | 24.98% |
| Return on Equity | 33.83% |
| Return on Assets | 14.03% |
Financials Score
| AltmanZ Score | 7.08 |
| Piotroski Score | 8.00 |
| Working Capital | 2.11B |
| Total Assets | 6.63B |
| Ebit | 1.22B |
| Market Cap | 29.46B |
| Total Liabilities | 3.68B |
Poll Results
About DexCom, Inc. (NASDAQ:DXCM) Stock
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, Dex ... Com, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
DXCM Secures Health Canada Authorization for Dexcom G7 15 Day CGM
2026-07-14 11:21:37
DexCom's G7 15 Day wins Health Canada authorization, offering longer wear, high accuracy and smart features for adults with diabetes.
2026-07-13 16:45:00
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi.
2026-07-09 09:00:00
[url="]DexCom, Inc.[/url] (NASDAQ: DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July
2026-07-09 08:30:00
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.
Here's Why DexCom (DXCM) is a Strong Growth Stock
2026-07-08 10:45:26
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
2026-07-06 15:36:19
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performance and a robust international foothold are expected to contribute further.
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
2026-07-03 12:27:00
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
DexCom: The Growth Thesis Still Needs To Be Proven
2026-07-02 02:10:16
DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market. DXCM aims to expand CGM adoption to Type 2 non-insulin patients, but commercial uptake remains unproven despite positive clinical trial results. At 28x earnings, DXCM's valuation is not demanding, yet offers limited upside given execution risks and the need for evidence of new market penetration.
Frequently Asked Questions
-
What is the current DexCom, Inc. (DXCM) stock price?
-
DexCom, Inc.(NASDAQ:DXCM) stock price is $72.73 in the last trading session. During the trading session, DXCM stock reached the peak price of $89.98 while $54.11 was the lowest point it dropped to. The percentage change in DXCM stock occurred in the recent session was --1.88% while the dollar amount for the price change in DXCM stock was -$-1.39.
-
DXCM's industry and sector of operation?
-
The NASDAQ listed DXCM is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of DXCM?
-
Christine Pospisil | Director of Medical Science & Education
Matthew Dolan | Executive Vice President of Strategy & Corporate Development
Michael Brown | Executive VP, Chief Legal & Compliance Officer
Sadie Stern | Executive VP, Chief People & Culture Officer
Kevin Ronald Sayer | Executive Chairman of the Board -
How many employees does DXCM have?
-
Number of DXCM employees currently stands at 11100. DXCM operates from 6340 Sequence Drive, San Diego, CA 92121, US.
-
Link for DXCM official website?
-
Official Website of DXCM is: https://www.dexcom.com
-
How do I contact DXCM?
-
DXCM could be contacted at phone #858 200 0200 and can also be accessed through its website. DXCM operates from 6340 Sequence Drive, San Diego, CA 92121, US.
-
How many shares of DXCM are traded daily?
-
The average number of DXCM shares traded daily for last 3 months was 5.74M.
-
What is the market cap of DXCM currently?
-
The market value of DXCM currently stands at $28.06B with its latest stock price at $72.73